AERIE PHARMACEUTICALS INC's ticker is AERI and the CUSIP is 00771V108. A total of 170 filers reported holding AERIE PHARMACEUTICALS INC in Q2 2019. The put-call ratio across all filers is 0.61 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $8,865,000 | -48.6% | 300,000 | +7.1% | 0.88% | -24.4% |
| Q3 2018 | $17,234,000 | +50.1% | 280,000 | +64.7% | 1.16% | -8.7% |
| Q2 2018 | $11,484,000 | +76.4% | 170,000 | +41.7% | 1.28% | +38.8% |
| Q1 2018 | $6,510,000 | +283.4% | 120,000 | +166.7% | 0.92% | +230.6% |
| Q3 2016 | $1,698,000 | -35.9% | 45,000 | -70.0% | 0.28% | -69.9% |
| Q2 2015 | $2,648,000 | – | 150,000 | – | 0.92% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management II, LLC | 805,217 | $14,212,000 | 4.99% |
| DAFNA Capital Management LLC | 156,842 | $2,768,000 | 2.34% |
| NORTHPOINTE CAPITAL LLC | 1,034,400 | $18,257,000 | 2.15% |
| HARVEY CAPITAL MANAGEMENT INC | 223,200 | $3,856,000 | 1.30% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,211,644 | $39,036,000 | 1.30% |
| Boulegeris Investments, Inc. | 88,660 | $1,565,000 | 1.12% |
| Partner Investment Management, L.P. | 43,623 | $770,000 | 1.08% |
| SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC | 150,000 | $2,648,000 | 0.92% |
| PFM Health Sciences, LP | 1,851,564 | $32,680,000 | 0.83% |
| Benchmark Capital Advisors | 55,400 | $978,000 | 0.69% |